Results 211 to 220 of about 1,913,070 (304)

Peripheral targets for neuropathic pain

open access: yesBritish Journal of Pharmacology, EarlyView.
Neuropathic pain represents a significant clinical challenge, with still limited pharmacological approaches to symptomatic relief. This review focuses on molecular targets implicated in neuropathic pain, particularly those involved in peripheral mechanisms. Using the IUPHAR/BPS database of biological targets, their occurrence together with ‘neuropathic
Amirhossein Afsharipour   +3 more
wiley   +1 more source

Thermodynamic characterisation of covalent ligand binding

open access: yesBritish Journal of Pharmacology, EarlyView.
Background and Purpose Differential scanning fluorimetry (DSF) is a common and straightforward method to evaluate the thermal stability of proteins and has been heavily used for ligand binding characterisation as well as for screening. One class of compounds that is less typically evaluated by DSF are covalent binders.
Rebecca Hertzman   +4 more
wiley   +1 more source

Pirtobrutinib in Richter syndrome: Outcomes from the named patient programme in Italy

open access: yes
British Journal of Haematology, EarlyView.
Isacco Ferrarini   +19 more
wiley   +1 more source

Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review

open access: yesBritish Journal of Pharmacology, EarlyView.
Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß   +3 more
wiley   +1 more source

NFкB pathway suppression as a key driver of pacritinib response in high‐risk myelofibrosis

open access: yes
British Journal of Haematology, EarlyView.
R. Van Dijck   +8 more
wiley   +1 more source

Bruton tyrosine kinase inhibitors and cardiovascular adverse events

open access: yesBritish Journal of Pharmacology, EarlyView.
Abstract Bruton tyrosine kinase inhibitors (BTKi) have transformed the management of chronic lymphocytic leukaemia and other B‐cell malignancies, yet their therapeutic benefit is tempered by clinically relevant cardiovascular toxicities (predominantly atrial fibrillation, hypertension, bleeding and ventricular arrhythmias).
Massimiliano Camilli   +4 more
wiley   +1 more source

The Unusual Coexistence of Chronic Lymphocytic Leukemia, Dengue Fever, and Acute Kidney Injury: A Case Report. [PDF]

open access: yesClin Case Rep
Khan M   +8 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy